Startup · $12.5m raised
Biotech developing pathology imaging technology for early cancer detection
Melbourne, VIC
Every investor coverage indicates participated in a round AlleSense raised.
| Investor | Rounds | Invested |
|---|---|---|
| Welcome Ventures | Unnamed stage · Series A | - |
| Breakthrough Victoria | Unnamed stage · Series A | $1,000,000 |
| Australian Economic Accelerator | Series A | $2,500,000 |
| AEA Innovate | Unnamed stage · Series A | $2,500,000 |
Companies AlleSense acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Eugeniu Balaur | Dr / Co-founder | Startup Daily (5 Aug 2026), Dealroom, Startup Daily (28 May 2026) |
| Julian Sutton | CEO (former) | Startup Daily (5 Aug 2026), Dealroom, Startup Daily (28 May 2026) |
| Professor Brian Abbey | Professor / Co-founder | Startup Daily (5 Aug 2026), Startup Daily (29 May 2026), Dealroom, Startup Daily (28 May 2026) |
| Rod Bristow | CEO (former) | Startup Daily |
Stories naming AlleSense. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech AlleSense, developing cancer pathology imaging tech, raised $5 million led by Welcome Ventures with Breakthrough Victoria and an AEA grant contributing.
La Trobe University spin-out AlleSense has secured $5 million to develop slide-based imaging for earlier cancer detection, led by Welcome Ventures with Breakthrough Victoria and the Australian Economic Accelerator's grant program also contributing.
Also Dealroom·Startup Daily
Breakthrough Victoria announces a $1 million investment in AlleSense, a La Trobe University spin-out developing nanofabricated slides for faster cancer diagnosis, joining round leader Welcome Ventures.